Glenmark Pharmaceuticals Limited
NSE:GLENMARK.NS
1393 (INR) • At close May 9, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 118,130.97 | 115,832.35 | 121,741.98 | 108,060.26 | 106,572.62 | 97,050.84 | 89,435.81 | 88,638.19 | 75,030.06 | 65,215.79 | 59,236.05 | 49,691.42 | 40,206.43 | 29,490.7 | 25,006.466 | 21,160.332 | 20,092.005 | 12,515.336 | 7,575.892 | 6,120.532 | 3,806.606 |
| Cost of Revenue
| 85,538.17 | 79,530.4 | 80,654.64 | 72,257.32 | 71,155.06 | 37,640.35 | 34,145.52 | 26,191.28 | 23,080.53 | 19,434.52 | 21,378.8 | 25,688.49 | 13,453.97 | 9,918.32 | 10,193.39 | 8,750.997 | 6,757.996 | 4,574.712 | 3,817.334 | 2,714.675 | 1,793.191 |
| Gross Profit
| 32,592.8 | 36,301.95 | 41,087.34 | 35,802.94 | 35,417.56 | 59,410.49 | 55,290.29 | 62,446.91 | 51,949.53 | 45,781.27 | 37,857.25 | 24,002.93 | 26,752.46 | 19,572.38 | 14,813.076 | 12,409.335 | 13,334.009 | 7,940.624 | 3,758.558 | 3,405.857 | 2,013.415 |
| Gross Profit Ratio
| 0.276 | 0.313 | 0.337 | 0.331 | 0.332 | 0.612 | 0.618 | 0.705 | 0.692 | 0.702 | 0.639 | 0.483 | 0.665 | 0.664 | 0.592 | 0.586 | 0.664 | 0.634 | 0.496 | 0.556 | 0.529 |
| Reseach & Development Expenses
| 12,258.29 | 12,500.35 | 12,787.08 | 13,186.91 | 13,205.12 | 14,480.26 | 12,251.33 | 12,622.33 | 8,175.9 | 6,014.42 | 5,998.06 | 4,115.59 | 0 | 0 | 772.758 | 882.703 | 757.73 | 432.609 | 263.344 | 326.512 | 248.073 |
| General & Administrative Expenses
| 2,631.09 | 3,039.99 | 4,006.96 | 3,172.64 | 3,650.65 | 2,753.92 | 2,070.27 | 2,222.52 | 1,932.3 | 1,590.19 | 921.04 | 966.02 | 0 | 0 | 7,844.662 | 6,976.794 | 0 | 0 | 0 | -14.678 | 0 |
| Selling & Marketing Expenses
| 10,922.73 | 11,371.96 | 8,963.07 | 9,432.14 | 7,038.54 | 8,709.42 | 7,628.87 | 8,425.27 | 6,580.92 | 4,648.35 | 3,645.16 | 3,786.13 | 0 | 0 | 0 | 0 | 4,571.018 | 3,245.159 | 2,123.161 | 1,521.825 | 1,074.266 |
| SG&A
| 13,553.82 | 14,320.44 | 10,505.97 | 6,099.39 | 10,689.19 | 28,737.78 | 9,699.14 | 10,647.79 | 8,513.22 | 15,453.6 | 19,409.29 | 11,489.55 | 0 | 0 | 7,844.662 | 6,976.794 | 4,571.018 | 3,245.159 | 2,123.161 | 1,507.147 | 1,074.266 |
| Other Expenses
| 0 | 0 | -277.44 | 468.65 | -197.41 | 293.78 | 0 | 13,585.15 | 13,496.43 | 16,828.18 | 3,875.09 | 0 | 20,495 | 13,191.27 | 716.469 | -713.289 | 890.273 | 649.673 | 251.337 | 299.256 | 176.846 |
| Operating Expenses
| 46,952.56 | 25,289.18 | 23,570.49 | 19,672.97 | 41,831.75 | 43,511.82 | 41,856.03 | 47,437.45 | 36,221.03 | 38,296.2 | 29,282.44 | 21,991.89 | 20,495 | 13,191.27 | 9,333.889 | 7,146.208 | 6,219.021 | 4,327.441 | 2,637.842 | 2,132.915 | 1,499.185 |
| Operating Income
| 6,310.73 | 10,788.74 | 18,400.48 | 17,160.36 | 12,820.89 | 15,898.67 | 13,434.26 | 14,794.01 | 11,760.5 | 7,830.02 | 8,788.26 | 8,894.64 | 6,257.46 | 6,380.94 | 5,479.187 | 5,263.127 | 7,114.988 | 3,613.183 | 1,120.716 | 1,272.942 | 514.23 |
| Operating Income Ratio
| 0.053 | 0.093 | 0.151 | 0.159 | 0.12 | 0.164 | 0.15 | 0.167 | 0.157 | 0.12 | 0.148 | 0.179 | 0.156 | 0.216 | 0.219 | 0.249 | 0.354 | 0.289 | 0.148 | 0.208 | 0.135 |
| Total Other Income Expenses Net
| -5,945.78 | -8,390.32 | -3,988.02 | -3,335.61 | -1,860.13 | -2,892.38 | -2,766.31 | -2,192.49 | -1,713.05 | -1,887.19 | -1,819.5 | -1,504.59 | -1,376.55 | -1,565.58 | -1,640.213 | -2,574.314 | 0 | 0 | 0 | 0 | 0 |
| Income Before Tax
| 364.95 | 2,398.42 | 14,412.46 | 13,824.75 | 10,960.76 | 13,006.29 | 10,667.95 | 12,601.52 | 10,047.45 | 5,942.83 | 6,968.76 | 7,390.05 | 4,880.91 | 4,815.36 | 3,838.974 | 2,688.813 | 7,114.988 | 3,613.183 | 1,120.716 | 1,272.942 | 514.23 |
| Income Before Tax Ratio
| 0.003 | 0.021 | 0.118 | 0.128 | 0.103 | 0.134 | 0.119 | 0.142 | 0.134 | 0.091 | 0.118 | 0.149 | 0.121 | 0.163 | 0.154 | 0.127 | 0.354 | 0.289 | 0.148 | 0.208 | 0.135 |
| Income Tax Expense
| 18,673.45 | 3,294.03 | 4,475.97 | 4,123.87 | 3,201.06 | 3,756.36 | 2,925.12 | 3,442.31 | 3,028.4 | 1,190.43 | 1,512.73 | 1,107.15 | 237.84 | 237.2 | 528.658 | 754.084 | 793.865 | 512.583 | 240.956 | 201.531 | 100.889 |
| Net Income
| -15,016.68 | 2,972.45 | 9,417.11 | 9,700.38 | 7,759.7 | 9,249.93 | 7,741.91 | 9,159.67 | 7,020.98 | 4,753.1 | 5,422.75 | 6,200.33 | 4,603.48 | 4,578.33 | 3,310.316 | 1,934.729 | 6,321.327 | 3,100.6 | 879.76 | 1,071.146 | 413.606 |
| Net Income Ratio
| -0.127 | 0.026 | 0.077 | 0.09 | 0.073 | 0.095 | 0.087 | 0.103 | 0.094 | 0.073 | 0.092 | 0.125 | 0.114 | 0.155 | 0.132 | 0.091 | 0.315 | 0.248 | 0.116 | 0.175 | 0.109 |
| EPS
| -53.22 | 10.53 | 33.37 | 34.38 | 27.5 | 32.78 | 27.44 | 32.46 | 25.01 | 17.52 | 20.01 | 22.91 | 17.03 | 16.78 | 12.4 | 7.7 | 25.8 | 12.99 | 3.64 | 4.49 | 1.76 |
| EPS Diluted
| -53.22 | 10.53 | 33.37 | 34.38 | 27.5 | 32.78 | 27.43 | 32.45 | 25 | 17.52 | 20 | 22.89 | 17.01 | 16.76 | 12.4 | 7.5 | 24.9 | 11.56 | 3.21 | 4.08 | 1.75 |
| EBITDA
| 11,343.7 | 11,580.52 | 22,260.6 | 21,791.42 | 18,905.6 | 19,611.19 | 17,064.29 | 20,739.9 | 14,471.61 | 10,444.13 | 11,022.65 | 10,207.35 | 7,325.36 | 7,366.69 | 6,685.291 | 5,120.406 | 8,464.851 | 4,419.848 | 1,510.236 | 1,601.386 | 725.738 |
| EBITDA Ratio
| 0.096 | 0.1 | 0.183 | 0.202 | 0.177 | 0.202 | 0.191 | 0.234 | 0.193 | 0.16 | 0.186 | 0.205 | 0.182 | 0.25 | 0.267 | 0.242 | 0.421 | 0.353 | 0.199 | 0.262 | 0.191 |